PlexusDx Oral Semaglutide users frequently report this window as the point where treatment feels sustainable rather than difficult
Why patients love it: Some people say they barely feel the needle here, making it a reassuring backup when the abdomen or thigh feels tender
Study limitations Although the current findings are consistent and coherent, strongly indicating the external validity of the study, we do recommend future preferably large prospective clinical trials, to increase their internal validity
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management (weight loss and weight maintenance) in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or greater (obesity) or 27 kg/m 2 or greater (excess weight) in the presence of at least one weight related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
A Danish registry of 84 000 adults on GLP-1 therapy for diabetes or obesity showed a 23 percent lower risk of hospitalizations for alcohol- or drug-related disorders than matched controls on other medications
